Raffaella Mastrocola, Manuela Aragno, Giuseppe Alloatti, Massimo Collino*, Claudia Penna and Pasquale Pagliaro Pages 1294 - 1310 ( 17 )
In the last decades, the extension of life expectancy and the increased consumption of foods rich in saturated fats and added sugars have exposed the general population to emerging health problems.
The prevalence of metabolic syndrome (MS), composed of a cluster of factors as obesity, dyslipidemia, hyperglycemia, and hypertension, is rapidly increasing in industrialized and developing countries leading to precocious onset of age-related diseases. Indeed, oxidative stress, accumulation of advanced glycation endproducts, and a chronic low-grade inflammation are common features of MS and physiological ageing. In particular, the entire set of MS factors contributes to the development of an inflammatory status named metaflammation, which has been associated with activation of early innate immune response through the assembling of the multiprotein complex inflammasome. The most investigated family of inflammasome platforms is the NOD-like receptor pyridine containing (NLRP) 3, which is activated by several exogenous and endogenous stimuli, leading to the sequential cleavage of caspase-1 and IL-1β, followed by secretion of active IL-1β. We here collect the most recent findings on NLRP3 activation in MS providing evidence of its central role in disease progression and organ dysfunction in target tissues of metaflammation, in particular in cardiovascular, hepatic and renal complications, with a focus on oxidative stress and advanced glycation endproducts. A wide overview of the most promising strategies for the modulation of NLRP3 activation and related metabolic repercussions is also provided, since the finding of specific pharmacological tools is an urgent requirement to reduce the social and economic burden of MS- and elderly-associated diseases.
Metabolic syndrome, metaflammation, NLRP3 inflammasome, oxidative stress, aging, myocardial ischemia/reperfusion, steatohepatitis, chronic kidney disease.
Department of Clinical and Biological Sciences, University of Turin, Torino, Department of Clinical and Biological Sciences, University of Turin, Torino, Department of Life Sciences and Systems Biology, University of Turin, Torino, Department of Drug Science and Technology, University of Turin, Torino, Department of Clinical and Biological Sciences, University of Turin, Torino, Department of Clinical and Biological Sciences, University of Turin, Torino